Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.4.3.4: monoamine oxidase

This is an abbreviated version!
For detailed information about monoamine oxidase, go to the full flat file.

Word Map on EC 1.4.3.4

Reaction

RCH2NHR'
+
H2O
+
O2
=
RCHO
+
R'NH2
+
H2O2

Synonyms

adrenaline oxidase, amine-oxygen oxidoreductase, C-MAO, EC 1.4.3.9, epinephrine oxidase, MAO, MAO A, MAO B, MAO type B, MAO-A, MAO-B, MAO-N, MAO-N-D5, MAOA, MAOB, monoamine oxidase, monoamine oxidase A, monoamine oxidase B, monoamine oxidase N, monoamine oxidase type B, monoamine oxidase-A, monoamine oxidase-B, monoamine oxidaseA, monoamine oxidases A, monoamine oxidases B, monoamine-oxidase-A, monoamine: O2-oxidoreductase, deaminated, monoamine: O2-oxidoreductase, deaminating, monoamine: O2-oxidoreductase: deaminating, monoamine:O2 oxidoreductase (deaminating), monoamine:O2 oxidoreductase, deaminating, monoamine:O2-oxidoreductase deaminating, monoaminoxidase B, More, semicarbazide-sensitive amine oxidase, serotonin deaminase, SSAO, tyraminase, tyramine oxidase, zMAO

ECTree

     1 Oxidoreductases
         1.4 Acting on the CH-NH2 group of donors
             1.4.3 With oxygen as acceptor
                1.4.3.4 monoamine oxidase

Inhibitors

Inhibitors on EC 1.4.3.4 - monoamine oxidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-amphetamine
reversible competitive inhibitor
(+/-)-6-hydroxytrypargine
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata, synthesized by reaction of 5-hydroxytryptamine hydrochloride with N-(3-[1,3]dioxolan-2-yl-propyl)-guanidine sulfate, overview
(-)-L-deprenyl
-
-
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
-
-
(1R,2R)-(-)-psi-ephedrine
-
IC50 for soluble enzyme: 5.03 mM, IC50 for immobilized enzyme: 88 mM, monoamine oxidase B; IC50 for soluble enzyme: 5.35 mM, IC50 for immobilized enzyme: 14.86 mM, monoamine oxidase A
(1S,2S)-(+)-psi-ephedrine
-
IC50 for soluble enzyme: 0.88 mM, IC50 for immobilized enzyme: 1.77 mM, monoamine oxidase A; IC50 for soluble enzyme: 10 mM, IC50 for immobilized enzyme: 234 mM, monoamine oxidase B
(1Z)-2-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.39
(2-methylprop-2-en-1-yl)hydrazine
-
(2-phenylprop-2-en-1-yl)hydrazine
-
(2E)-1,3-diphenylprop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
-
-
(2E)-1-(4-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(2E)-1-[4-(benzyloxy)phenyl]-3-(4-chlorophenyl)prop-2-en-1-one
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-(3-hydroxyphenyl)ethanamide
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-phenylethanamide
-
-
(2E)-2-[(1H-indol-3-yl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 10% inhibition; 0.1 mM, pH 7.4, 43% inhibition
-
(2E)-2-[(2-chloro-3-methoxyphenyl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 17% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
0.1 mM, pH 7.4, 32% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
-
-
(2E)-2-[1-(2,4,5-trifluorophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 23% inhibition
-
(2E)-2-[1-(2,4-dihydroxy-5-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 30% inhibition; 0.1 mM, pH 7.4, 8% inhibition
-
(2E)-2-[1-(4-chloro-3-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 13% inhibition; 0.3% inhibition
-
(2E)-2-[1-(4-iodophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 25% inhibition
-
(2E)-2-[1-[3-(dihydroxyamino)-4-methoxyphenyl]ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 19% inhibition; 0.1 mM, pH 7.4, 37.2% inhibition
-
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
-
-
(2E)-3-(2-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
-
(2E)-3-(3-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
-
inhibits MAO-A and MAO-B
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
-
-
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
-
(2E,4E)-5-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)penta-2,4-dienamide
i.e. guineensine, isolated from dried fruits of Piper longum, competitive inhibition; i.e. guineensine, isolated from dried fruits of Piper longum, competitive inhibition
(2E,4E,12E)-13-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)trideca-2,4,12-trienamide
i.e. methylpiperate, isolated from dried fruits of Piper longum, competitive inhibition; i.e. methylpiperate, isolated from dried fruits of Piper longum, competitive inhibition
(2E,6E)-farnesol
-
-
(2R)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2R)-1-cyclohexyl-N-methyl-N-(1H-pyrrol-2-ylmethyl)propan-2-amine
-
(2S)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
-
i.e. safinamide, a potent selective and reversible MAO-B inhibitor, occurs in two polymorphic forms. Both forms are orthorhombic and regarded as conformational polymorphs due to the differences in the orientation of the 3-fluorobenzyloxy and propanamide groups. Both structures pack with layers in the ac plane, structure overview
(2S)-amphetamine
-
-
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
1% inhibition of isoform MAO-B at 0.01 mM, 14% inhibition of isoform MAO-A at 0.01 mM
(3E)-3-[2-(isopropylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
4% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
-
6%inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
-
13% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
-
10% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
-
2% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
-
(3E)-7-hydroxy-3-[(4-methoxyphenyl)methylidene]-2,3-dihydro-4H-1-benzopyran-4-one
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
17% inhibition of isoform MAO-B at 0.01 mM
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(4-[[bis(methylene)(4-methylphenyl)-lambda6-sulfanyl]oxy]phenoxy)hydrazine
0.1 mM, complete inhibition
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(5E)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(3-bromobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(4-chlorobenzylidene)-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-2,5-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-benzylidene-2-imino-1,3-thiazolidin-4-one
-
-
(5E)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-[(3,5-dibromo-4-hydroxycyclohexa-1,4-dien-1-yl)methylidene]-1,3-thiazolidine-2,4-dione
-
-
(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
IC50: 0.001mM, at 0.15 mM kynuramine
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
-
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
L136468, binding mode, overview
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
A6355
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
L136662
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
AS605240, binding mode, overview
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
(6-butoxy-2-naphthyl)-2-aminopropane
-
(6-ethoxy-2-naphthyl)-2-aminopropane
-
(6-methoxy-2-naphthyl)-2-aminopropane
-
(6-methylthio-2-naphthyl)isopropylamine
-
(6-propoxy-2-naphthyl)-2-aminopropane
-
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(aminomethyl)trimethylsilane
-
-
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine
-
-
(E)-3-(2-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3,4-dimethoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(diethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(dimethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-chlorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-fluorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(10-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(5-(1,2,3,4-tetrahydroacridin-9-ylamino)pentyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(8-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(9-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methylbenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-5-(3-chlorostyryl)isatin
-
(E)-5-(3-fluorostyryl)isatin
-
(E)-5-styrylisatin
-
(E)-6-styrylisatin
-
(E)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(3,4,5-trimethoxybenzylidene)chroman-4-one
-
(E)-7-(6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(4-methoxybenzylidene)chroman-4-one
-
(E)-7-(8-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)3-(4-methoxybenzylidene)chroman-4-one
-
(E)-8-(2-furylethenyl)caffeine
-
-
(E)-8-(2-thienylethenyl)caffeine
-
-
(E)-8-(3,4-dichlorostyryl)caffeine
-
-
(E)-8-(3,5-ditrifluoromethylstyryl)caffeine
-
-
(E)-8-(3-bromostyryl)caffeine
-
-
(E)-8-(3-chlorostyryl)caffeine
(E)-8-(3-methylstyryl)caffeine
-
-
(E)-8-(3-trifluoromethylstyryl)caffeine
-
-
(E)-8-(4-chlorostyryl)caffeine
-
-
(E)-8-(4-fluorostyryl)caffeine
-
-
(E)-8-(4-methylstyryl)caffeine
-
-
(E)-8-(4-trifluoromethylstyryl)caffeine
-
-
(E)-8-styrylcaffeine
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
-
-
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
-
-
(N-cyclopropyl-alpha-methylbenzylamine)
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
(R)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(R)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(R)-amphetamine
-
IC50 for soluble enzyme: 0.0311 mM, IC50 for immobilized enzyme: 0.0991 mM, monoamine oxidase A; IC50 for soluble enzyme: 0.246 mM, IC50 for immobilized enzyme: 4.03 mM, monoamine oxidase B
(R)-deprenyl
(R)-N-(alpha-cyclohexylethyl),N-methyl-1H-pyrrole-2-carboxamide
-
(R)-N-(alpha-cyclohexylethyl)-1H-pyrrole-2-carboxamide
-
(R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
-
specific inhibitor of isoform MAO-B
(R,S)-amphetamine
-
IC50 for soluble enzyme: 0.0031 mM, IC50 for immobilized enzyme: 0.0244 mM, monoamine oxidase A; IC50 for soluble enzyme: 0.0625 mM, IC50 for immobilized enzyme: 3 mM, monoamine oxidase B
(S)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(S)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)-benzo[d]isoxazol-3-yl]-oxazolidin-2-one
-
SL25.1188, inhibits MAO-B in the brain with 50% unspecific binding, overview
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo; i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,10 phenanthroline
-
weak inhibition
1,2,3,4-tetrahydroacridin-9-amine
-
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
1,3,7-trimethyl-8-[(E)-2-(3-thienyl)vinyl]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3-dimethyl-5-nitro-1H-indazole
-
-
1,3-dimethyl-6-phenyl-1H-pteridine-2,4-dione
-
-
1,3-diphenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0098 mM, MAO-A; IC50: 0.2 mM, MAO-B
1,4-diphenyl-1,3-butadiene
1,4-diphenyl-2-butene
1-(1-methylhydrazino)-3-(phenylthio)propan-2-ol
-
-
1-(1-methylhydrazino)-3-[methyl(phenyl)amino]propan-2-ol
-
-
1-(1-naphthyl)-2-aminopropane
-
1-(2-naphthyl)-2-aminopropane
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
-
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
1-(4-butoxyphenyl)-2-aminopropane
-
1-(4-chlorobutyl)-5-nitro-1H-indazol-3-ol
-
-
1-(4-ethoxyphenyl)-2-aminopropane
-
1-(4-guanidinobutoxy)-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-(4-methoxy-phenyl)-2-aminopropane
-
1-(4-methylthiophenyl)-2-aminopropane
-
1-(4-propoxyphenyl)-2-aminopropane
-
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
1-acetyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000009 mM, MAO-A; IC50: 0.041 mM, MAO-B
1-acetyl-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00023 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(2,5-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0002 mM, MAO-A; IC50: 0.14 mM, MAO-B
1-acetyl-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00029 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(2-nitrophenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0003 mM, MAO-A; IC50: 0.09 mM, MAO-B
1-acetyl-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.088 mM, MAO-B
1-acetyl-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00024 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.00001mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0002 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.02 mM, MAO-B
1-acetyl-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-5-(2,4-dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.00001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-5-(2-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0001 mM, MAO-A; IC50: 0.038 mM, MAO-B
1-acetyl-5-(3,4-dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.00001 mM, MAO-A; IC50: 0.025 mM, MAO-B
1-acetyl-5-(3-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000009 mM, MAO-A; IC50: 0.083 mM, MAO-B
1-acetyl-5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000008 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-amino-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-benzyl-5-nitro-1H-indazol-3-ol
-
-
1-guanidino-6-hydroxy-3,5-dihydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
-
-
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
-
-
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-3-(3-methylphenyl)pyrrole
-
-
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methyl-2-[(E)-2-(4-methylphenyl)vinyl]-1H-benzimidazole
-
-
1-methyl-2-[(E)-2-phenylvinyl]-1H-benzimidazole
-
-
1-methyl-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1H-benzimidazole
-
-
1-methyl-3-(3-bromophenyl)pyrrole
-
-
1-methyl-3-(3-chlorophenyl)pyrrole
-
-
1-methyl-3-(3-fluorophenyl)pyrrole
-
-
1-methyl-3-(3-methylphenyl)-1H-pyrrole
-
-
1-methyl-3-(3-methylphenyl)pyrrole
-
-
1-methyl-3-(3-trifluoromethylphenyl)pyrrole
-
-
1-methyl-3-(4-methylphenyl)-1H-pyrrole
-
-
1-methyl-3-phenyl-1H-pyrrole
-
-
1-methyl-3-phenylpyrrole
-
-
1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrrole
-
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
-
1-methyl-4-phenylpyridinium
-
1-methyl-5-nitro-1H-indazol-3-ol
-
inhibits MAO-B by 34% at 0.015 mM
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
-
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor; non-selective inhibitor
1-O-n-octyl-beta-D-glucopyranoside
-
at concentrations well below the critical micelle concentration
1-phenyl-2-aminopropane
-
1-phenyl-N-(1H-pyrrol-2-ylmethyl)methanamine
-
1-phenylcyclopropylamine
the inhibitor forms an irreversible flavin adduct
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A; monoamine oxidase B
1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3-(4-chlorophenoxy)-2-methoxypropyl]-1-methylhydrazine
-
-
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
11H-indolo[3,2-c]cinnoline
29% inhibition at 0.05 mM
2,2'-bipyridyl
-
50% inhibition at 1 mM
2,2'-dipyridyl disulfide
-
-
2,2-dibutyl-3-acetyl-5-(3,5-dimethylphenyl)-1,3,4-oxadiazoline
-
0.8 mM, 42.8% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,3,5-trifluoro-4-methoxybenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 82% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamid
-
1 mM, 72% inhibition
2,2-dibutyl-5-(4-chlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 59% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(furan-2-yl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 73% inhibition
2,4-dichloro-N'-(nonan-5-yl)benzohydrazide
-
-
2,4-dichlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.92
2,4-dichlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.03
2,4-dimethoxy-5-hydroxybenzaldehyde
IC50: 0.042 mM, monoamine oxidase A; IC50: 0.39 mM
2,6-dimethoxyphenol
IC50: 0.0624 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
2-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.0001 mM, MAO-A; IC50: 0.019 mM, MAO-B
2-(1-acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
IC50: 0.001 mM, MAO-A; IC50: 0.07 mM, MAO-B
2-(1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.000072 mM, MAO-A; IC50: 0.04 mM, MAO-B
2-(2,4-dichlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
6164872
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
6163851
2-(2-benzofuranyl)-2-imidazoline
at micromolar concentrations, to a site distinct from the active site on at least two forms of the pure enzyme, probably corresponding to oxidised and reduced enzyme states
2-(2-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-ethoxylpyridin-3-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,4,5-trimethoxyphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,5-dimethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3-methylphenyl)-4-(butoxycarbonylethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
12% inhibition at 0.001 mM; 5% inhition at 0.001 mM
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
2-(4'-butoxyphenyl)thiomorpholin-5-one
2-(4'-butoxyphenyl)thiomorpholine oxalate
2-(4'-ethoxyphenyl)thiomorpholin-5-one
2-(4'-ethoxyphenyl)thiomorpholine oxalate
2-(4'-methoxyphenyl)thiomorpholin-5-one
2-(4'-methoxyphenyl)thiomorpholine oxalate
2-(4'-propoxyphenyl)thiomorpholin-5-one
2-(4'-propoxyphenyl)thiomorpholine oxalate
2-(4,5-dihydroimidazol-2-yl)-isoquinoline
reversible non-competitive/mixed inhibitor
2-(4,5-dihydroimidazol-2-yl)-quinoline
reversible non-competitive/mixed inhibitor
2-(4-bromophenyl)cyclopropanamine
-
2-(4-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
selective for MAO-B
2-(4-ethylphenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-ethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-fluorophenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-methoxyphenyl)cyclopropanamine
-
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
-
-
2-(5,7-dibromobenzofuran-2-yl)-imidazoline
reversible non-competitive/mixed inhibitor
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
-
-
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
2-(aminooxy)-1-phenylethanol
-
2-(benzo[d][1,3]dioxol-5-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
-
-
2-(naphthalen-1-yl)cyclopropanamine
-
2-(naphthalen-2-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(thiophen-3-yl)cyclopropanamine
-
2-bromo-N-(2-morpholinoethyl)nicotinamide
-
2-bromo-N-(3-morpholinopropyl)nicotinamide
-
2-Bromoethylamine
-
complete inhibition at 0.01 mM
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
-
2-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
2-chloro-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-N-(3-morpholinopropyl)nicotinamide
-
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-ethoxy-N'-(nonan-5-yl)nicotinohydrazide
-
-
2-ethylaminobenzylamine dihydrochloride
-
2-hydrazinyl-4-(3-nitrophenyl)-1,3-thiazole
0.1 mM, pH 7.4, 10% inhibition; 0.1 mM, pH 7.4, 6% inhibition
-
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
2-hydroxyquinoline
-
reversible by dialysis
2-methoxyphenol
IC50: 0.175 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
2-methyl-5-methylaniline
IC50: 0.15 mM, monoamine oxidase A; IC50: above 0.5 mM
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
2-methylaminobenzylamine dihydrochloride
-
2-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.45
2-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.18
2-oxo-2H-chromen-7-yl benzenesulfonate
-
2-oxo-N-(2,3,5,6-tetrafluoropyridin-4-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(pentafluorophenyl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(propan-2-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-[3-(trifluoromethyl)phenyl]-2H-chromene-3-carboxamide
-
-
2-oxo-N-[4-(propan-2-yl)phenyl]-2H-chromene-3-carboxamide
-
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
46% inhibition at 0.05 mM
2-phenyl-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-phenyl-5H-indeno[1,2-d]pyrimidine
37% inhibition at 0.02 mM
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
2-phenylcyclopropylamine
2-Phenylethylamine
time-dependent, slowly reversible suicide inhibition. Addition of 2-phenylethylamine (10mM) to the enzyme results in immediate bleaching of the absorbance peak at 460 nm, a consequence of rapid reduction of the flavin cofactor by 2-phenylethylamine at steady state
2-phenylthiomorpholin-5-one
2-phenylthiomorpholine oxalate
2-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dien-1-yl]-3,5,7-trimethyl-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
-
-
2-[(E)-2-(4-bromophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-chlorophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-fluorophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-methoxyphenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[1-(4-chlorophenyl)-5-(2,3-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.008 mM, MAO-A; IC50: 0.3 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.009 mM, MAO-A; IC50: 0.3 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0094 mM, MAO-A; IC50: 0.48 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.025 mM, MAO-B; IC50: 0.097 mM, MAO-A
2-[1-(4-chlorophenyl)-5-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.098 mM, MAO-A; IC50: 2.0 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.013 mM, MAO-A; IC50: 3.8 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.09 mM, MAO-A; IC50: 1.0 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.094 mM, MAO-A; IC50: 1.8 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.088 mM, MAO-A; IC50: 0.2 mM, MAO-B
2-[1-(4-chlorophenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0095 mM, MAO-A
2-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000086 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.00001 mM, MAO-A; IC50: 0.0001 mM, MAO-B
2-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000008 mM, MAO-A; IC50: 0.019 mM, MAO-B
2-[1-acetyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0001 mM, MAO-A; IC50: 0.04 mM, MAO-B
2-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000028 mM, MAO-A; IC50: 0.00006 mM, MAO-B
2-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000009 mM, MAO-A; IC50: 0.0072 mM, MAO-B
2-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.002 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000088 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.06 mM, MAO-B
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[4-(trifluoromethyl)phenyl]cyclopropanamine
-
2-[5-(3-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.089 mM, MAO-A; IC50: 0.25 mM, MAO-B
2-[5-(4-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.12 mM, MAO-A; IC50: 1 mM, MAO-B
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
-
-
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
-
-
2-{1-(4-chlorophenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl}phenol
IC50: 0.4 mM, MAO-B
2-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
3,4,5-trimethoxy-N'-(nonan-5-yl)benzohydrazide
-
-
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
-
-
3,4-dimethoxyaniline
IC50: 0.131 mM, monoamine oxidase A
3,4-dimethoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.88
3,4-dimethoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.52
3,4-dimethyl-2-oxo-2H-chromen-7-yl 4-methoxybenzenesulfonate
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl benzenesulfonate
-
3,4-dimethyl-7-(2-oxo-2-phenylethoxy)-2H-chromen-2-one
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
pIC50 for MAO-A: 4.99; pIC50 for MAO-B: 7.57
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
pIC50 for MAO-A: 5.15; pIC50 for MAO-B: 6.34
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
pIC50 for MAO-A: 4.5; pIC50 for MAO-B: 5.49
3,4-dimethyl-7-[(3-nitrobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-[(pentafluorobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one
-
3,5,7-trimethyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
3,5-bis(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3,5-di-2-thienyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
-
-
3,5-dimethyl-N'-(nonan-5-yl)benzohydrazide
-
-
3,5-diphenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(2,4-dimethoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0018 mM, MAO-A; IC50: 0.04 mM, MAO-B
3-(2-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.01 mM, MAO-A; IC50: 0.5 mM, MAO-B
3-(2-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(2-naphthyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(3,4-dimethoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.003 mM, MAO-A; IC50: 0.017 mM, MAO-B
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
12% inhibition at 0.01 mM; 17% inhibition at 0.01 mM
3-(3-bromophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-chlorophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-fluorophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-fluorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-methoxyphenyl)-1-methyl-1H-pyrrole
-
-
3-(3-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000014 mM, MAO-A; IC50: 0.001 mM, MAO-B
3-(3-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-methylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.09 mM, MAO-A; IC50: 0.98 mM, MAO-B
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
3% inhibition at 0.01 mM
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
23% inhibition at 0.01 mM
3-(3-tert-butylphenyl)-1-methyl-1H-pyrrole
-
-
3-(4-bromophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0074 mM, MAO-A; IC50: 0.087 mM, MAO-B
3-(4-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-chlorophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0099 mM, MAO-A; IC50: 0.1 mM, MAO-B
3-(4-chlorophenyl)-5-(4-fluorocyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-chlorophenyl)-5-(4-methoxycyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-chlorophenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-chlorophenyl)-5-cyclohexa-1,5-dien-1-yl-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-fluorophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-fluorophenyl)-5-(2-furyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H -pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxycyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-hydroxyphenyl)-2-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoic acid
-
-
3-(4-hydroxyphenyl)propionic acid
-
-
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
-
-
3-(4-methoxybenzyl)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
3-(4-methoxyphenyl)-1-methyl-1H-pyrrole
-
-
3-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.00011 mM, MAO-A; IC50: 0.0125 mM, MAO-B
3-(4-methoxyphenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
3-(4-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-methylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.0069 mM, MAO-A; IC50: 0.05 mM, MAO-B
3-(4-nitrophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
IC50: 0.000086 mM, MAO-A; IC50: 0.00145 mM, MAO-B
3-(4-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(5-oxo-5H-indeno[1,2-c]pyridazin-3-yl)benzonitrile
-
3-(benzyloxy)-5-nitro-1H-indazole
-
-
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(benzyloxy)-6a,10a-dihydro-6H-benzo[c]chromen-6-one
-
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-amino-4-aminomethylpyridine dihydrochloride
-
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
-
-
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-benzyl-5-nitro-1H-indazole
-
-
3-benzyl-5H-indeno[1,2-c]pyridazin-5-one
-
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-hydroxyphenylacetic acid
-
-
3-methoxy-1-methyl-5-nitro-1H-indazole
-
inhibits MAO-B by 52% at 0.015 mM
3-methoxy-5-nitro-1H-indazole
-
-
3-methoxyphenol
IC50: 0.024 mM, monoamine oxidase A
3-methyl-5-nitro-1H-indazole
-
-
3-methyl-8-(4,4,4-trifluoro-butoxy)indeno[1.2-c]pyridazin-5-one
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
3-phenyl-4-(phenylseleno)isoquinoline
reversibly inhibits isoform MAO-B activity
3-phenyl-4-(phenylthio)isoquinoline
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
21% inhibition at 0.01 mM
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
12% inhibition at 0.01 mM
3-[(5E)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]propanenitrile
-
-
3-[(5E)-5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
R598127
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
-
-
3-[(E)-2-phenylvinyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[2-(ethylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
17% inhibition of isoform MAO-A at 0.01 mM
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
31% inhibition of isoform MAO-A at 0.01 mM
3-[4-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[[4-(trifluoromethyl)phenoxy]methyl]-5H-indeno[1,2-c]pyridazin-5-one
48% inhibition at 0.01 mM
3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride
-
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,2,3-triol
IC50: 0.0001 mM, MAO-A; IC50: 0.39 mM, MAO-B
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.08 mM, MAO-B
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.00005 mM, MAO-A; IC50: 0.062 mM, MAO-B
4-(1-acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.03 mM, MAO-B
4-(1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
IC50: 0.000073 mM, MAO-A; IC50: 0.003 mM, MAO-B
4-(2,4-dichlorophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 25% inhibition; 0.1 mM, pH 7.4, 31% inhibition
-
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(2-bromophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 24% inhibition
-
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
-
-
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenylseleno)-3-phenylisoquinoline
-
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
-
-
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
4-([6-[(4-cyanophenyl)methoxy]-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
-
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
-
-
4-benzyl-1-cyclopropyl-1,2,3,6-tetrahydropyridine
-
-
4-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
4-chloro-N-(2-morpholinoethyl)nicotinamide
-
4-chloro-N-(3-morpholinopropyl)nicotinamide
-
4-chlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.42
4-chlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-Cyanophenol
4-ethyl-N'-(nonan-5-yl)benzohydrazide
-
-
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
IC50: 0.0089 mM, monoamine oxidase B; IC50: 0.0134 mM, monoamine oxidase A
4-Hydroxy-3-methoxybenzylamine
IC50: 0.13 mM, monoamine oxidase A; IC50: 0.382 mM, monoamine oxidase B
4-hydroxy-3-methoxyphenethyl alcohol
IC50: 0.18 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenyl acetone
IC50: 0.0302 mM, monoamine oxidase A
4-hydroxyphenylacetic acid
-
-
4-methoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.72
4-methoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.3
4-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.69
4-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.67
4-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-oxo-4H-chromene-3-carboxylic acid
-
specific for MAO-B
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
-
-
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
-
-
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
-
-
4-[(methylamino)carbonyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
9% inhibition of isoform MAO-B at 0.01 mM, 8% inhibition of isoform MAO-A at 0.01 mM
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[1-(cyclopropylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-(ethylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.0001 mM, MAO-A; IC50: 0.038 mM, MAO-B
4-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.00001 mM, MAO-A; IC50: 0.02 mM, MAO-B
4-[1-acetyl-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000086 mM, MAO-A; IC50: 0.087 mM, MAO-B
4-[1-acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000008 mM, MAO-A; IC50: 0.13 mM, MAO-B
4-[1-acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0000088 mM, MAO-A; IC50: 0.1 mM, MAO-B
4-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.00001 mM, MAO-A; IC50: 0.00002 mM, MAO-B
4-[1-acetyl-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.00001 mM, MAO-A; IC50: 0.023 mM, MAO-B
4-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000013 mM, MAO-A; IC50: 0.000038 mM, MAO-B
4-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000008 mM, MAO-A; IC50: 0.019 mM, MAO-B
4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.00001 mM, MAO-A; IC50: 0.12mM, MAO-B
4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0001 mM, MAO-A; IC50: 0.04 mM, MAO-B
4-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000009 mM, MAO-A; IC50: 0.083 mM, MAO-B
4-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.000009 mM, MAO-A; IC50: 0.0072 mM, MAO-B
4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
IC50: 0.000009 mM, MAO-A; IC50: 0.042 mM, MAO-B
4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
IC50: 0.0001mM, MAO-A; IC50: 0.03 mM, MAO-B
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[4-(benzyloxy)phenoxy]hydrazino]butanenitrile
0.1 mM, 39% inhibition
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]methyl]benzonitrile
-
-
4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid
-
-
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
-
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
-
5,7-diethyl-3-methyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
5-(2-furyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(2-furyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
i.e. rosiglitazone
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-chlorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorophenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-fluorophenyl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-hydroxy-3,5-dimethylbenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methylcyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methylcyclohexa-1,5-dien-1-yl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-(4-methylphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. ciglitazone
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. troglitazone
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. pioglitazone, docking of R-pioglitazone in the substrate cavity of MAO-B
5-(aminomethyl)-3-aryl-2-oxazolidinones
-
-
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2-chlorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
5-bromo-N-(2-morpholinoethyl)nicotinamide
-
5-bromo-N-(3-morpholinopropyl)nicotinamide
-
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
-
-
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
5-cyclohexa-1,5-dien-1-yl-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-cyclohexa-1,5-dien-1-yl-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-cyclohexa-1,5-dien-1-yl-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
5-fluoro-alpha-methyltryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
5-fluorotryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
5-nitro-1-(pyridin-2-ylmethyl)-1H-indazol-3-ol
-
-
5-nitroindazole
-
inhibits MAO-B by 98.5% at 0.015 mM
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-1,3-thiazolidine-2,4-dione ammoniate (1:1)
-
-
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-2-imino-1,3-thiazolidin-4-one
-
-
6,11-dihydro-5H-benzo[a]carbazole
38% inhibition at 0.025 mM
6-(3-chlorophenyl)-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
6-amino-1,3-dimethyl-5-([1-phenylmeth-(E)-ylidene]-amino)-1H-pyrimidine-2,4-dione
-
-
6-amino-1,3-dimethyl-5-[(E)-3-phenyl-prop-2-en-(E)-ylideneamino]-1H-pyrimidine-2,4-dione
-
-
6-amino-5-([1-(3-chlorophenyl)-meth-(E)-ylidene]-amino)-1,3-dimethyl-1H-pyrimidine-2,4-dione
-
-
6-amino-5-[(E)-3-(3-chloro-phenyl)-prop-2-en-(E)-ylideneamino]-1,3-dimethyl-1H-pyrimidine-2,4-dione
-
-
6-chloro-N-(2-morpholinoethyl)nicotinamide
-
6-chloro-N-(3-morpholinopropyl)nicotinamide
-
6-fluoro-alpha-methyltryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
6-fluoro-N-(2-morpholinoethyl)nicotinamide
-
6-fluoro-N-(3-morpholinopropyl)nicotinamide
-
6-fluorotryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
6-hydroxy-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
6-methyl-N-(2-morpholinoethyl)nicotinamide
-
6-methyl-N-(3-morpholinopropyl)nicotinamide
-
6-nitroindazole
-
inhibits MAO-B by 89% at 0.015 mM, also inhibits MAO-A
6-[(3-iodophenyl)methoxy]-3-[(3-iodophenyl)methyl]quinazolin-4(3H)-one
-
-
6-[(3-iodophenyl)methoxy]quinazolin-4(3H)-one
-
-
6-[(4-fluorophenyl)methoxy]-3-[(4-fluorophenyl)methyl]quinazolin-4(3H)-one
-
-
6-[(E)-2-(3-chloro-phenyl)-vinyl]-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
6-[(E)-2-(3-chlorostyryl)]-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 4.9; pIC50 for MAO-B: 8.29
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-formylcoumarin
-
-
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.5; pIC50 for MAO-B: 6.95
7-(anilinomethyl)-2H-chromen-2-one
-
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.55; pIC50 for MAO-B: 6.06
7-(benzylamino)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-2H-chromen-2-one
-
7-(benzyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-4-methyl-2H-chromen-2-one
-
7-(benzyloxy)-4-phenyl-2H-chromen-2-one
-
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
-
-
7-benzenesulfonyloxy-2H-chromen-2-one
pIC50 for MAO-A: 6.35; pIC50 for MAO-B: 4.26
7-benzyloxy-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 5.26; pIC50 for MAO-B: 8.18
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.73; pIC50 for MAO-B: 5.56
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.0; pIC50 for MAO-B: 7.4
7-nitroindazole
-
inhibits MAO-B by 35% at 0.015 mM
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
-
-
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
-
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
8-(-3-chlorostyryl)-caffeine
by means of its dual action as A2A antagonist and MAO-B inhibitor 8-(-3-chlorostyryl)-caffeine reverses behavior and biochemical alterations, observed in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of Parkinson's disease
8-(3-chloro)styrylcaffeine
-
-
8-(3-chlorostrylyl)caffeine
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
8-(3-chlorostyryl)-caffeine
-
-
8-(3-chlorostyryl)caffeine
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-hydroxyquinoline
-
reversible by the addition of Zn2+, Ni2+, Co2+
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
9,11-dimethylpurino[7,8-c]quinazoline-8,10(9H,11H)-dione
-
-
Acetylcholine
competitively inhibits monoamine oxidase A in the brain in a tissue-dependent manner, inhibition of MAO-A in cerebellum; competitively inhibits monoamine oxidase B in the brain in a tissue-dependent manner, inhibition of MAO-B in basal ganglia
acridine
Acridine orange
acridine yellow
-
-
Acriflavin
-
irreversible inhibitor
Acriflavine
-
-
alpha-Naphthol
aminoguanidine
-
complete impairment of SSAO activity produced by aminoguanidine-treatment in obese rats is likely responsible for a weak limitation of fat deposition. Aminoguanidine may be useful for treating obesity via its SSAO blocking properties
amitriptyline
competive inhibition with 2-phenylethylamine as substrate
amphetamine
Azure Blue
-
-
befloxatone
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site
benzaldehyde
-
strong competitive inhibitor
benzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 8.14
benzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 5.92
benzhydrylidene-prop-2-ynyl-amine
-
-
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
pIC50 for MAO-A: 5.02; pIC50 for MAO-B: 5.62
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
benzyl cyanide
-
reversible inhibitor
benzylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview; the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
beta-carbolines
-
competitive reversible and potent inhibitor
beta-naphthol
beta-phenylethylidenehydrazine
a neuroprotective drug, inhibits MAO-A by 26.7%; a neuroprotective drug, inhibits MAO-B by 14.9%
brofaromine
Caffeine
CdSO4
-
1 mM, 10% inhibition, monoamine oxidase B; 1 mM, 90% inhibition with serotonin as substrate, monoamine oxidase A
chlorgilin
chlorgylin
-
-
chlorgyline
ciglitazone
-
-
cinnamyl alcohol
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
cis-2,4,5-trimethoxypropenylbenzene
IC50: 0.142 mM, monoamine oxidase A; IC50: 0.362 mM, monoamine oxidase B
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
cis-N-benzyl-2-methoxycyclopropylamine
high inhibitory action, exhibits a poor isozyme selectivity; high inhibitory action, exhibits a poor isozyme selectivity
-
clorgiline
-
-
Clorgyline
clorogyline
-
-
CuSO4
-
1 mM, 95% inhibition with serotonin as substrate, monoamine oxidase A
cyanidin
-
competitive interaction of cyanidin with MAO A plus a mixed competitive and non-competitive mode of interaction of cyanidin with MAO B
cyanidin-3,5-diglucoside
-
-
cyanidin-3-O-beta-D-galactoside
-
-
cyanidin-3-O-beta-D-glucoside
-
mixed competitive and non-competitive mode of interaction with both enzyme isozymes
cyanidin-3-O-beta-D-rutinoside
-
-
cyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.69
cyclopentanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.85
D-amphetamine
dehydroepiandrosterone
at 0.1 mM, inhibition of MAO-A by 44.2%; at 0.1 mM, inhibition of MAO-B by 61.2%
delphinidin
-
-
delphinidin-3-O-beta-D-glucoside
-
-
deoxycholate
-
-
deprenil
Deprenyl
di(2-hydroxyethyl)methyldodecylammonium
reversible competitive inhibitor
di(2-hydroxyethyl)methyldodecylammonium ion
-
a biocide, inhibits MAO-B
epigallocatechin gallate dimer
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
esuprone
-
inhibits MAO-A reversibly
ethyl 4-hydroxy-3-methoxycinnamate
IC50: 0.0057 mM, monoamine oxidase B; IC50: 0.0247 mM, monoamine oxidase A
ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate
-
-
ethyl-4-hydroxy-3-methoxyphenylacetate
IC50: 0.081 mM, monoamine oxidase A
eugenol
IC50: 0.0344 mM, monoamine oxidase A; IC50: 0.288 mM, monoamine oxidase B
eugenol methyl ether
IC50: 0.11 mM, monoamine oxidase A; IC50: 0.269 mM, monoamine oxidase B
farnesol
-
-
fumarate
-
-
Harmaline
harmalol
-
identification by HPLC-ESI-mass spectrometry
harman
Harmane
harmine
harmol
-
identification by HPLC-ESI-mass spectrometry
indol -2,3-dione
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
Iproniazid
iproniazid phosphate
-
Iproniazide
isatin
isocarboxazide
isoproniazid
-
inhibits MAO-A and MAO-B irreversibly
KF-17837
KW-6002
L-deprenyl
ladostigil
lamotrigine
its in vivo MAO-B inhibiting effect might contribute in part to its antidepressant activity
lazabemide
LU-53439
-
inhibits MAO-B reversibly
malvidin
-
-
malvidin 3-O,5-O-di-beta-D-glucoside
-
-
malvidin-3-O-beta-D-galactoside
-
-
malvidin-3-O-beta-D-glucoside
-
-
Mesobuthus gibbosus venom peptide
-
with specific MAO-A inhibitory activity, reversible, non-competitive, may be responsible for the anxiogenic effects of the scorpion venom on animals and humans
-
metamphetamine
i.e. N-methyl-1-phenyl-2-propanamine; i.e. N-methyl-1-phenyl-2-propanamine
-
metanephrine
IC50: 0.252 mM, monoamine oxidase A
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
-
-
methylene blue
moclobemide
mofegiline
N'-(2-cyanoethyl)-4-ethylbenzohydrazide
-
-
N'-(nonan-5-yl)-2-naphthohydrazide
-
-
N'-(nonan-5-yl)benzo[d][1,3]dioxole-5-carbohydrazide
-
-
N'-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carbohydrazide
-
-
N,1-dimethyl-N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide
-
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
IC50: 0.09 mM, at 0.15 mM kynuramine
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
IC50: 0.0005 mM, at 0.15 mM kynuramine
N-((4-isopropylphenyl)-2-oxo-2H-chromene-3-carboxamide)-amide
-
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-3-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-3, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-A
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-2, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-B
N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
-
N-(1H-pyrrol-2-ylmethyl)prop-2-yn-1-amine
-
N-(2,3-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-difluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-4-chlorobenzamide
-
N-(2-aminoethyl)-aryl-carboxamide
-
N-(2-aminoethyl)-p-chlorobenzamide
N-(2-benzylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-chloro-6-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-cyclohexylethyl)-N-methyl-1H-pyrrole-2-carboxamide
-
N-(2-methyl-1H-indol-5-yl)benzamide
-
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
-
N-(2-methyl-6-chlorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-6-chlorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-morpholinoethyl)nicotinamide
-
N-(2-phenylethyl),N-methyl-1H-pyrrole-2-carboxamide
-
N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
N-(3,4-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-8-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-8-methyl-2-oxo-7-(2-phenylethyl)-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethyl-2-oxo-2H-chromen-7-yl)benzamide
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
pIC50 for MAO-A: 5.34; pIC50 for MAO-B: 4.5
N-(3,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
N-(3-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-morpholinopropyl)nicotinamide
-
N-(3-phenylpropyl),N-methyl-1H-pyrrole-2-carboxamide
-
N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
-
N-(3-trifluoromethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}phenyl)acetamide
-
N-(4-benzyloxybenzyl)-4-methylthioamphetamine
-
N-(4-butoxybenzyl)-4-methylthioamphetamine
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-hydroxybenzyl)-4-methylthioamphetamine
weak inhibition of MAO-A; weak inhibition of MAO-B
N-(4-isopropylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methanesulfonylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methoxybenzyl)-4-methylthioamphetamine
-
N-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-phenylbutyl),N-methyl 1H-pyrrole-2-carboxamide
-
N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
-
N-(biphenyl-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(butan-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
-
-
N-(prop-2-ynyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-([(5S)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-([(5S)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-2-phenylethyl-1H-pyrrole-2-carboxamide
-
N-benzyl,N-methyl-1H-pyrrole-2-carboxamide
-
N-benzyl-(4-methylthioamphetamine)
weak inhibition of MAO-A; weak inhibition of MAO-B
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine
most selective MAO-A inhibitor
N-benzyl-12-isothiocyanato-N-methyldodecan-1-amine
irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B; irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B
N-benzyl-1H-pyrrole-2-carboxamide
-
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine
-
N-benzyl-N-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methylprop-2-yn-1-amine
-
i.e. pargyline
N-benzylprop-2-yn-1-amine
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclohexyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-isobutyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isopropyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methoxy-2-(3-methylphenyl)maleimide
-
-
N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine
pH 7.4, 38°Cmost selective MAO-B inhibitor
N-methyl-1-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
N-methyl-2-(3-bromophenyl)maleimide
-
-
N-methyl-2-(3-chlorophenyl)maleimide
-
-
N-methyl-2-(3-fluorophenyl)maleimide
-
-
N-methyl-2-(3-methylphenyl)maleimide
-
-
N-methyl-2-(3-trifluoromethylphenyl)maleimide
-
-
N-methyl-2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
N-methyl-2-phenylmaleimide
-
-
N-methyl-3-phenyl-N-(1H-pyrrol-2-ylmethyl)propan-1-amine
-
N-methyl-4-phenyl-N-(1H-pyrrol-2-ylmethyl)butan-1-amine
-
N-methyl-N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
-
N-methyl-N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]prop-2-yn-1-amine
-
N-phenyl-1H-indazole-5-carboxamide
N-phenyl-1H-pyrrole-2-carboxamide
-
N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide
-
N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-propargyl-l(R)-aminoindan
i.e. rasagiline. N-Propargyl-l(R)-aminoindan is well tolerated and effective in the treatment of early Parkinson's disease and as adjunctive treatment in levodopa-treated patients with Parkinson's disease experiencing motor fluctuations
N-[(1R)-1-cyclohexylethyl]-1H-pyrrole-2-carboxamide
-
N-[(1S)-1-cyclohexylethyl]-1H-pyrrole-2-carboxamide
-
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
-
i.e. clorgiline
N-[4-(methylsulfonyl)phenyl]-2-oxo-2H-chromene-3-carboxamide
-
-
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
-
N1,N12-dibenzyldodecane-1,12-diamine
-
N1-(3-aminopropyl)-N4-(3-((naphthalen-2-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((pyridin-3-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((thiophen-2-ylmethyl)amino)propyl)butane-1,4-diamine
mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B; mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B
N1-benzyl-spermine
-
naringenin
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions; the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
norharman
NW 1772
-
specific inhibitor of isoform MAO-B
o-eugenol
IC50: 0.101 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
oleamide
-
inhibits MAO B
p-(propylthio)-phenylisopropylamine
-
p-nitrobenzylamine
substrate for wild-type enzyme, competitive inhibitor for mutant enzyme Y435L
Pargyline
ParSL
pelargonidin
-
-
pelargonidin 3-O,5-O-di-beta-D-glucoside
-
-
peonidin
-
-
peonidin-3-O-beta-D-glucoside
-
-
petunidin
-
-
Phenelzine
phenelzine sulfate
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal; mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pheniprazine
phentermine
Phenylethylhydrazine
phenylhydrazine
pioglitazone
-
pirlindole
an MAO A specific reversible inhibitor
pirlindole mesylate
Proflavin
-
irreversible inhibitor
Proflavine
-
-
pyronine G
R-(-)-deprenyl
R-deprenyl
-
-
R-rasagiline
-
-
raisin extract
-
-
rasagiline
rhodiocyanoside A
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rhodioloside B
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
Ro 19-6327
-
-
Ro 41-1049
rosiglitazone
-
-
rosiridin
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
safinamide
salidroside
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
sanguinarine
-
-
selegiline
selegilline
-
specific inhibitor of isoform MAO-B
sembragiline
-
-
Semicarbazide
Sodium diethyldithiocarbamate
-
weak inhibition
succinate
-
-
syringic acid
-
-
takrin
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
non-selective; non-selective
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
selective for MAO-B
tetrahydroharmine
-
identification by HPLC-ESI-mass spectrometry
tetrahydropyridines
-
-
tetrindole
tetrindole mesylate
toloxatone
trans,trans-farnesol
monoamine oxidase B
trans-2,4,5-trimethoxypropenylbenzene
IC50: 0.124 mM, monoamine oxidase A; IC50: 0.338 mM, monoamine oxidase B
trans-2-phenylcyclopropylamine
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
trans-trans-1,4-diphenyl-1,3-butadiene
-
-
tranylcypromine
tranylcypromine hydrochloride
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal; mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
triandrin
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
troglitazone
-
-
tyrosol
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
vanillic acid
-
-
ZnSO4
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
R598119
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
[(E)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[(E)-N-bis-(2-propynyl)-2-(phenyl)ethyidene]hydrazine
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[(Z)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
[4-(benzyloxy)phenoxy]hydrazine
0.1 mM, 43% inhibition
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
-
additional information
-